First-pass extracted concept

T cell engagers

Candidate: concept label1 source documents4 linked claims

Jump to explainers Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

TCEs

Extracted Explainers

What the tool is doing

T cell engagers redirect T cells to kill tumor cells. The abstract presents them as a therapeutic class rather than a single discrete tool.

Source 1DOI PubMed

What problem it solves

They aim to harness T cells for tumor cell killing in cancer immunotherapy.

Source 1DOI PubMed

What it does not solve

Conventional TCEs remain limited by CRS, on-target off-tumor toxicity, and immunosuppressive tumor settings.

Source 1DOI PubMed

Alternatives

The abstract contrasts next-generation TCE designs with conventional TCEs, but does not name non-TCE alternative modalities.

Source 1DOI PubMed

Evidence Snippets

T cell engagers (TCEs) are a promising class of cancer immunotherapy that re-direct T cells to kill tumor cells.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 4 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1design strategysupports2025Source 1DOI PubMed

Optimizing geometry to facilitate effective immune synapses, affinity optimization of the anti-CD3/TCR domain, and targeting specific T cell subsets aim to reduce cytokine release syndrome in T cell engager design.

Claim 2forward looking statementsupports2025Source 1DOI PubMed

Next-generation T cell engagers are expected to overcome some limitations of conventional T cell engagers, enhance the therapeutic window, and enable combination therapies.

Claim 3functionsupports2025Source 1DOI PubMed

T cell engagers redirect T cells to kill tumor cells.

Claim 4limitationsupports2025Source 1DOI PubMed

Clinical application of T cell engagers is limited by cytokine release syndrome, on-target off-tumor toxicity, and the challenge of overcoming immunosuppression in hematological and solid tumors.